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Abstract
Background: An appropriate transcriptional profile in the placenta and fetal membranes is required for successful
pregnancy; any variations may lead to inappropriate timing of birth. Epigenetic regulation through reversible
modification of chromatin has emerged as a fundamental mechanism for the control of gene expression in a
range of biological systems and can be modified by pharmacological intervention, thus providing novel therapeutic
avenues. TIMP-1 is an endogenous inhibitor of MMPs, and hence is intimately involved in maintaining the integrity
of the fetal membranes until labor.
Objective and Methods: To determine if TIMP-1 is regulated by DNA methylation in gestational tissues we
employed an in vitro model in which gestational tissue explants were treated with demethylating agent 5-aza-2'-
deoxycytidine (AZA) and lipopolysaccharide (LPS).
Results: Quantitative Real-Time PCR (qRT-PCR) revealed that TIMP-1 transcription was significantly increased by
combined treatment of AZA and LPS, but not LPS alone, in villous, amnion and choriodecidua explants after 24
and 48 hrs, whilst western blotting showed protein production was stimulated after 24 hrs only. Upon interrogation
of the TIMP-1 promoter using Sequenom EpiTyper MassARRAY, we discovered sex-specific differential methylation,
in part explained by x-linked methylation in females. Increased TIMP-1 in the presence of LPS was potentiated
by AZA treatment, signifying that a change in chromatin structure, but not in DNA methylation at the promoter
region, is required for transcriptional activators to access the promoter region of TIMP-1.
Conclusions: Collectively, these observations support a potential role for pharmacological agents that modify
chromatin structure to be utilized in the therapeutic targeting of TIMP-1 to prevent premature rupture of the fetal
membranes in an infectious setting.
Keywords: TIMP1, Placenta, Labour, Epigenetics, Infection
Background
The end of human gestation is signified by the physio-
logical hallmarks of uterine contractions and rupture of
the fetal membranes (amnion and chorion) [1]. These
two processes are essential for the advancement of labor,
and inappropriate timing of these processes may lead to
premature or post-term birth, both of which have
adverse consequences for the neonate [1, 2].
Matrix metalloproteinase (MMP) mediated extracellular
matrix (ECM) degradation plays a key role in normal
growth and remodelling of fetal membranes throughout
gestation and at term, and are critically involved in the
weakening and subsequent rupture of the fetal mem-
branes at the time of labor [3]. Locally produced tissue
inhibitors of metalloproteinases (TIMPs) function as
critical modulators of both normal and pathological tissue
remodelling. As TIMPs bind MMPs in a 1:1 stoichiometric
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fashion, thus an imbalanced MMP:TIMP ratio can result in
tissue degradation.
TIMP-1 levels decrease in the amniotic fluid with
advancing gestation, concomitant with a marked in-
crease in MMP-9 prior to the onset of labor [4–8].
Increased MMPs, particularly MMP-9, in fetal mem-
brane rupture at both preterm and term labor is well
documented [6, 7, 9–13] and the MMP-9:TIMP-1 ratio
in fetal membranes at term gestation correlates with
their tensile strength [14]. Furthermore, this altered
MMP-9:TIMP-1 ratio is exacerbated in the presence of
infection [7, 15–19].
Preterm rupture of the fetal membranes (PROM) oc-
curs in as many as 15 % of all pregnancies and is associ-
ated with 25-50 % of preterm births [20, 21]. The
etiology of preterm labor is complex and multifactorial,
however intrauterine infection caused by bacteria is the
leading identifiable cause [1, 22]. Lipopolysaccharide
(LPS), an endotoxin on the outer surface of gram nega-
tive bacteria, has been implicated in the mechanism re-
sponsible for PROM and preterm delivery [23, 24].
Epigenetic regulation through the reversible modifica-
tion of chromatin has emerged as a fundamental mech-
anism for the control of gene expression in a range of
biological systems. DNA methylation is the covalent
modification of post-replicative DNA by the addition of
a methyl group to the cytosine ring to form methyl cyto-
sine, usually in the context of CpG dinucleotides.
Discrete CpG rich regions, approximately 1 kb in size,
are known as CpG islands (CGIs) and occur in more
than half of the genes in the vertebrate genome [25].
CGIs are usually unmethylated, and the extent of methyla-
tion in promoter regions is generally inversely correlated
with gene activity [26, 27]. Epigenetic modifications are
subject to both developmental and environmental regula-
tion, are reversible and can potentially be modified,
thereby making them an attractive target for therapeutic
interventions.
DNA methylation is essential for normal development
of extra-embryonic tissues, particularly the invasive be-
havior of trophoblast cells [28]. The placenta is unique
in that it is hypomethylated compared to somatic tissues
[29, 30], and DNA methylation is positively correlated
with gestational age [31, 32]. This suggests that there are
consistent and large scale changes to DNA methylation
in the placenta throughout pregnancy, contributing to
differential global gene expression across gestation [33]
and at term prior to, and following, spontaneous labor
and delivery [34, 35].
Silencing of TIMP-1 by promoter methylation is a fea-
ture of cancer cells, and treatment with demethylating
agent AZA results in the induction of TIMP-1 in a num-
ber of cancer cell lines [36–40] as well as endometrial
stromal cells [38].
Given that aberrant placental methylation has been
associated with adverse pregnancy outcomes [39–41],
and TIMP-1 is regulated by DNA methylation in other
tissues; we hypothesize that TIMP-1 is regulated by
DNA methylation in the placenta and fetal membranes,
and that this regulation is altered in the presence of
infection.
Methods
Tissue Collection and explant system
Gestational tissues (villous placenta and fetal membranes)
were collected from women at term with uncomplicated,
singleton pregnancies (38-40 weeks gestation) following
elective caesarean section (pre-labor, CS) and after vaginal
delivery from women with spontaneous onset of labor
(post-labor and delivery, SVD). Indications for cesarean
section were breech presentation or previous cesarean
section delivery. Women were excluded from the study if
they had a twin pregnancy, became pregnant using in vitro
fertilization, suffered any pregnancy complications includ-
ing preeclampsia or gestational diabetes, were a current
smoker, or smoked up until, or during any part of their
pregnancy. Ethical approval for the study was obtained
from NorthernX Regional Ethics Committee (NTX/10/
07/062/AM03) and tissues were collected following
written informed consent. All the participants have given
consent to publish the data. The fetal membranes were
separated into amnion and chorion (with the immediately
adjacent decidua attached, herein referred to as choriode-
cidua), and all tissues were rinsed in PBS to remove
maternal blood. Tissues from both CS and SVD
deliveries were snap frozen and stored at -80 C until
further analysis. Tissues from CS deliveries were
cultured using a previously published in vitro tissue
explant system [42–44] with modifications as follows.
Samples of villous tissue were taken randomly across
the placenta from mid-sections of cotyledons (halfway
between the maternal and fetal sides). Large vessels were
removed using blunt dissection leaving only villous tis-
sue, which was further dissected into 20 mg pieces. Fetal
membranes were separated into amnion and choriodeci-
dua and 6 mm tissue discs were excised using a sterile
cork borer. Villous, amnion and choriodecidua explants
were plated separately (six pieces per well) and
equilibrated in DMEM/F12 containing L-Glutamate
(Life Technologies, Carlsbad, CA, USA) with 10 % FBS
(Life Technologies) and 1 % Penstrep solution (final con-
centrations 100 U/ml Penicillin and 100 μg streptomy-
sin; Life Technologies) in a humidified atmosphere of
5 % CO2 and 8 % O2 for 24 hrs.
After equilibration, tissues were washed and media were
replaced with DMEM/F12 supplemented with 0.1 % bo-
vine gamma globulin (Sigma–Aldrich, St. Louis, MO,
USA) containing 5 μM AZA (Sigma–Aldrich) or DMSO
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as the control (Sigma–Aldrich). Media for all treatments
contained 0.05 % DMSO. The dose and length of AZA
treatment was based on previous publications [45]. Fol-
lowing 48 hrs culture, tissues were extensively washed in
sterile PBS and tissues were further incubated in the pres-
ence or absence of 5 μg/ml LPS (E.coli, Sigma–Aldrich).
Tissues were cultured with LPS to determine if an inflam-
matory response induced changes in TIMP-1 expression
and/or DNA methylation. Control tissues were cultured
in DMSO only for the duration of the culture period, with
exception of the initial 24 hrs equilibration period. Culture
was terminated at 24 hrs and 48 hrs post LPS treatment,
tissues were snap frozen and conditioned media reserved.
Tissues and media samples were stored at -80C and -20C
respectively.
Glucose uptake by tissue explants
Tissue viability was assessed by glucose uptake in condi-
tioned media from explant experiments (Reti, Lappas,
Huppertz, et al., 2007). Glucose uptake was measured
by enzymatic colourimetric assay (Roche, Mannheim,
Germany) on a Hitachi 902 autoanalyser (Hitachi High
Technologies Corporation, Tokyo, Japan). Data were
normalised to wet tissue weight and minutes (Table 1).
RNA Extraction and Real time PCR
Total RNA was isolated from tissues using Trizol® (Life
Technologies) according to manufacturer’s instructions.
RNA concentrations were quantified using a NanoDrop
ND-1000 spectrophotometer (NanoDrop, Thermo Scien-
tific, USA). Reverse transcription and cDNA synthesis was
performed using Transcriptor First Strand cDNA Synthe-
sis Kit (Roche Applied Sciences, Penzberg, Germany) ac-
cording to manufacturer’s instructions using 1 μg of total
RNA for each preparation. The resulting cDNA was
stored at -20C until required.
TIMP-1 expression was analysed by Quantitative Real-
Time PCR (qRT-PCR) using the LightCycler 480, Light-
Cycler 480 SYBR Green Master Mix (Roche Applied
Sciences). Gene specific primers used for qRT-PCR are
as follows. TIMP-1: sense 5’-TCTGGCATCCTGTTG
TTGCT-3’; antisense 5’-CGCTGGTATAAGGTGGTC
TGG-3’. RPLPO: sense 5’-AGAAACTGCTGCCTCAT
ATCCG-3’; antisense 5’-CCCCTGGAGATTTTAGTGG
TGA-3’. RPL13a: sense 5’-GCCCTACGACAAGAAAA
AGCG-3’; antisense 5’-TACTTCCAGCCAACCTCGTGA-
3’ (Integrated DNA Technologies, Custom Science,
Auckland, New Zealand). Primer specificity was confirmed
by the Massey Genome Service at Massey University,
Palmerston North, New Zealand. RPLPO and RPL13a
were used as endogenous controls to normalise gene
expression. The average transcript quantity in tissues
collected from CS and SVD deliveries and in treated tissue
explants was calculated using the relative standard curve
method and Delta-delta CT method respectively, normal-
ised to the geometric mean of the endogenous controls.
Western blotting
Western blotting was performed on whole cell lysates using
rabbit monoclonal anti-TIMP-1 antibody (ab109125,
Abcam, Cambridge, UK). Samples were separated by
weight by SDS-PAGE using 4-12 % Bis-Tris gels (Life
Technologies), and transferred onto PVDF membrane.
Following pre-incubation with a blocking solution, mem-
branes were incubated in primary antibody overnight. The
membranes were then extensively washed, incubated in
HRP-conjugated secondary antibody (A5045, Sigma Al-
drich) and were visualized using Pierce SuperSignal West
Dura Extended Duration Substrate (Thermo Scientific,
Illinois, USA). Relative protein levels were obtained
using densitometric quantification (Quantity One soft-
ware; Bio-Rad Laboratories, Hercules, California, USA)
and were normalized to beta actin.
DNA Extraction and Methylation Analysis
Genomic DNA was extracted from tissues using Qiagen
QiaAMP DNA extraction kit (QIAGEN, Hilden,
Germany) as per manufacturers’ instructions. DNA con-
centrations were quantified using a NanoDrop ND-1000
spectrophotometer.
Methylation analysis using the Sequenom™ EpiTyper®
MassARRAY platform was undertaken by the Australian
Genome Research Facility (AGRF; www.agrf.org.au).
Sequenom primers specific to two regions of the TIMP-
1 gene were designed in-house by AGRF. Region A is
upstream from the transcription start site (-275/-1)
covering 11 CpGs and Region B includes the TIMP-1
promoter and first exon, covering 14 CpGs (Fig. 1).
Methylation analysis was carried out on bisulphite con-
verted DNA, using 200 ng for each preparation.
Table 1 Glucose uptake by gestational tissue explants
24 hrs 48 hrs
Control AZA LPS AZA + LPS Control AZA LPS AZA + LPS
Placenta 0.80 ± 0.13 0.92 ± 0.09 0.79 ± 0.08 0.86 ± 0.06 0.43 ± 0.04 0.63 ± 0.02 0.49 ± 0.05 0.48 ± 0.06
Amnion 0.98 ± 0.02 0.92 ± 0.02 0.86 ± 0.03 0.91 ± 0.02 0.84 ± 0.02 0.85 ± 0.01 0.76 ± 0.02 0.73 ± 0.01
Choriodecidua 0.43 ± 0.03 0.47 ± 0.07 0.41 ± 0.06 0.40 ± 0.06 0.38 ± 0.05 0.41 ± 0.04 0.39 ± 0.03 0.45 ± 0.04
Glucose uptake by placenta, amnion and choriodecidua explants was measured in conditioned culture media by enzymatic colourimetric assay.
Data are presented as glucose uptake μmol/mg/min (mean ± SEM; n = 8)
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Methylation levels for each CpG unit are expressed as a
percentage which is calculated from the ratio mass signals
between methylated and non-methylated DNA in each
sample.
Statistical Analysis
Data are presented as means ± SEM and statistical com-
parisons between groups were performed using non-
parametric Kruskal Wallis ANOVA (1-way analysis of
variance) with Dunn’s post-hoc test using GraphPad
Prism (GraphPad Software, La Jolla California USA,
www.graphpad.com). An alpha value of less than 0.05
was considered significant.
Results
Expression of TIMP-1 in Gestational Tissues in relation to
labor
TIMP-1 mRNA levels were significantly higher in villous
tissues collected from elective caesarean section deliver-
ies, prior to the onset of labor (CS) compared to tissues
collected following spontaneous vaginal delivery (SVD).
This trend was observed also in choriodecidua, but not
in amnion tissues (Fig. 2a). Tissues from both CS and
SVD had significantly higher TIMP-1 mRNA in female
amnion compared to male amnion (Fig. 2b and c).
Effect of AZA and LPS treatments on TIMP-1 transcription
and protein production
Placenta, amnion and choriodecidua tissues pre-treated
with AZA and subsequently treated with LPS for both
24 hrs and 48 hrs significantly increased TIMP-1 mRNA
expression compared to controls (Fig. 3). LPS treatment
alone, without pre-treatment of AZA, had no effect on
TIMP-1 transcription. Further scrutiny of the data re-
vealed a greater stimulation of TIMP-1 transcription in
male villous and amnion that were pre-treated with
AZA compared to female tissues in 48 hour treated
tissues (Fig. 3d and e).
Villous and amnion explants pre-treated with AZA and
subsequently incubated in the presence of LPS for 24 hrs
had significantly higher TIMP-1 protein production com-
pared to controls (Fig. 4a and b). As with the mRNA, LPS
treatment alone had little effect on TIMP-1 protein pro-
duction in villous (Fig. 4a) or amnion explants (Fig. 4b)
however did significantly increase TIMP-1 protein in
choriodecidual explants following 24 hrs incubation
(Fig. 4c). No changes in TIMP-1 protein production were
observed in tissues cultured with LPS for 48 hrs (Fig. 4).
Fig. 1 Schematic of the TIMP-1 gene promoter and locations of primers used for methylation analysis. Region A is upstream of the transcription
start site (-275/-1) and covers 11 CpGs, Region B (+1/+279) covers the TIMP-1 promoter and first exon and contains 14 CpGs. The numbered line
represents the distance in base pairs from the transcription start site, shown by the number 0. CpGs are represented by open circles
Fig. 2 TIMP-1 mRNA Expression in Term Villous Placenta, Amnion and Choriodecidua measured by qRT-PCR. a Tissues collected prior to the onset
of labor from elective Caesarean sections deliveries (CS, n = 14) are shown by the white bars. Tissues collected following the spontaneous onset
of labor from vaginal deliveries (SVD, n = 10) are shown by grey bars. TIMP-1 transcription was further analysed by sex of the fetus in b CS deliveries
(Male n = 8, Female n = 6) and c SVD (Male n = 5 and Female n = 5). Data are presented as mean ± SEM * P≤ 0.05. All results were normalised to the
expression of endogenous controls (RPLPO and RPL13a)
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Similar to the mRNA data, there appears to be a sex-
specific response of TIMP-1 protein production to the
treatments, particularly in male choriodecidua treated
for 48 hrs (Fig. 4f ). Although notable, high variations
among sample groups prevent statistical significance.
Methylation analysis of TIMP-1
Methylation within the TIMP-1 promoter was signifi-
cantly higher in amnion from CS deliveries compared to
SVD (17 % and 8 % respectively) (Fig. 5a). Villous and
placenta from pregnancies with a male fetus were hypo-
methylated compared to tissues from pregnancies with
female fetuses in both CS and SVD samples (CS villous
male 3.5 %, female 7.8 %; CS amnion male 3.9 %, female
25.9 %; SVD villous male 3.7 %, female 8.9 %; SVD am-
nion male 3.2 %, female 24 %). Choriodecidua from
pregnancies with male fetuses were hypomethylated
compared to choriodecidua from pregnancies with fe-
male fetuses in SVD alone (16 % and 22 %, respectively)
(Fig. 5b and c). This was evident in both regions of the
TIMP-1 promoter analysed (only data from region B is
shown). The percentage methylation of each CpG is
shown in the representative epigram for each tissue
(Fig. 5d).
Cultured villous placenta and amnion from pregnan-
cies with male fetuses were hypomethylated compared
to tissues from female pregnancies (on average: villous
male 4.7 %, female 9.6 %; amnion male 5.35 %, female
29.5 %; Fig. 6a and b). Amnion from pregnancies with
female fetuses cultured in the presence of LPS had
significantly higher methylation compared to controls
(34.6 % and 20.6 %, respectively; Fig. 6b). Methylation of
choriodecidua from pregnancies with female fetuses was
significantly higher following treatment with AZA and
LPS compared to choriodecidua from pregnancies with
male fetuses (26.8 % and 19.2 %, respectively; Fig. 6c).
Discussion
The present study investigated the regulation of TIMP-1
by DNA methylation with or without infection in the
human placenta and fetal membranes. We observed a
labor effect on TIMP-1 transcription in villous placenta,
and discovered sex-specific differential expression in am-
nion collected both prior to and post labor and delivery.
Fig. 3 TIMP-1 mRNA expression as fold change compared to controls in gestational tissues measured using qRT-PCR. Tissues were cultured in the
presence of lipopolysaccharide (LPS, 5 μg/ml) with/without prior treatment with 5-aza-deoxycytidine (AZA, 5 μM; n = 8). a Villous placenta b Amnion
and c Choriodecidua, and further analysed by the sex of the fetus in d Villous placenta e Amnion and f Choriodecidua. Tissues from pregnancies with
male fetuses (n = 5) are shown by white bars and those from pregnancies with female fetuses (n = 3) are shown by cross-hatched bars. Data are
calculated as fold change compared to time matched DMSO treated control, represented by the dotted line, and presented as mean ± SEM * P≤ 0.05,
** P≤ 0.01, *** P≤ 0.001. All results were normalised to the expression of endogenous controls (RPLPO and RPL13a)
Vincent et al. Reproductive Biology and Endocrinology  (2015) 13:136 Page 5 of 11
There were subtle differences in methylation in all tis-
sues in relation to labor status, which was discordant
with the gene expression observed. The TIMP-1 pro-
moter was generally hypomethylated, particularly in vil-
lous placenta, however sex specific methylation patterns
were observed. Methylation in villous placenta and am-
nion from pregnancies with female fetuses was markedly
higher than tissues from pregnancies with male fetuses,
whereas the levels in choriodecidua were comparable.
Treatment with demethylating agent AZA followed by
incubation with LPS significantly increased TIMP-1
mRNA, and to a lesser extent protein, in cultured tissue
explants. Villous placenta and amnion from pregnancies
with male fetuses showed greater stimulation of TIMP-1
transcription following 48 hrs of treatment. This is the
first study to show sex-specific expression patterns of
TIMP-1 in term gestational tissues.
TIMP-1 is on the X chromosome and is consequently
subject to X chromosome inactivation in females. The
fact that higher methylation levels were observed in fe-
male tissues in this study was not surprising, as methyla-
tion of X-linked genes is enriched on the inactivated X
chromosome [46, 47]. However, not all X-linked genes
are completely silenced, and TIMP-1 is reported to dis-
play variable inactivation due to both changes in methy-
lation and chromatin structure [48, 49]. With the
exception of genes which do escape X inactivation, X-
linked promoters should show limited methylation in
males and partial methylation in females [50]. X-linked
methylation explains the differences in methylation ob-
served in tissues from pregnancies with male or female
tissues collected prior to, and post labor and delivery,
and the associated discordant gene expression seen in
amnion samples. However, complete inactivation of one
X-chromosome should result in a gene showing at least
50 % methylation, which was not the case in all tissues
from pregnancies with female fetuses tested, thus sug-
gesting variable inactivation.
A comparison of autosomal and X-lined genes showed
that methylation of placental promoters is reduced only
on the X chromosome, and is particularly evident in fe-
males resulting from an X- specific methylation decrease
[51]. Due to the fact that X-linked placental genes are
not usually over expressed, other epigenetic marks, such
as chromatin modifications and non-coding RNA, are
likely involved in the silencing of X-linked genes,
Fig. 4 TIMP-1 protein measured by western blotting in treated explant samples shown as fold change compared to controls. Tissues were
cultured in the presence of lipopolysaccharide (LPS, 5 μg/ml) with/without prior treatment with 5-aza-deoxycytidine (AZA, 5 μM; n = 8). a Villous
placenta b Amnion and c Choriodecidua and further analysed by the sex of the fetus in d Villous placenta e Amnion and f Choriodecidua. Tissues
from pregnancies with male fetuses (n = 5) are shown by white bars and those from pregnancies with female fetuses (n = 3) are shown by cross-hatched
bars. Data are calculated as fold change compared to time matched DMSO treated control, represented by the dotted line, and presented as mean ± SEM
* P≤ 0.05. All results were normalised to beta actin optical density
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including chromatin changes and non-coding RNA [52].
It is possible that other epigenetic marks are regulating
TIMP-1 in the placenta.
The levels of methylation we observed in choriodeci-
dua samples did not differ between tissues from preg-
nancies with male or female pregnancies. This could be
explained in part by the contamination of adjacent ma-
ternal cells in the tissue sample. The chorion is closely
associated to maternal decidua cells, which are firmly
adhered to the chorion membrane. Due to tissue explant
system used, it was not possible to separate the fetal cells
from the maternal cells, thus no analysis could be car-
ried out on the contribution of either cell’s contribution
to the gene expression observed. It would therefore be
an interesting avenue for future studies to investigate.
Despite the presence of maternal cells in male tissue
samples, as there is still one active allele in maternal tis-
sues the X-linked methylation cannot alone account for
the lessened response of TIMP-1 transcription and pro-
tein to treatments seen in cultured tissue explants from
pregnancies with female fetuses when compared to tis-
sues from pregnancies with male fetuses. However, the
greater response observed in tissues from pregnancies
with male fetuses could simply be due to them being
more susceptible to the LPS treatment [53].
Tissue and sex-specific differential methylation was
observed in both tissues collected at term prior to, and
post labor and delivery, and in treated explants. In-
creased gene expression in the presence of greater
methylation could be due to the mixture of silent meth-
ylated cells and expressing unmethylated cells in the tis-
sues [54]. It is becoming increasing apparent that DNA
methylation may not just function in gene silencing, in-
creased methylation has been associated with enhanced
gene expression for several genes including IL8, EGRF-2,
HLA-DRA and GPH-α [55–59].
Fig. 5 Percentage methylated CpGs in the TIMP-1 Promoter in term villous placenta, amnion and choriodecidua collected prior to, or post labor
and delivery. a Tissues collected prior to the onset of labor from elective Caesarean sections deliveries (CS, n = 14) are shown by the white boxes.
Tissues collected following the spontaneous onset of labor from vaginal deliveries (SVD, n = 10) are shown by grey boxes. TIMP-1 methylation fur-
ther analysed by sex of the fetus in b CS deliveries (Male n = 8, Female n = 6) and c SVD (Male n = 5 and Female n = 5). Tissues from pregnancies
with male fetuses are shown by white or grey bars and those from pregnancies with female fetuses are shown by cross-hatched bars. d Repre-
sentative epigrams show the % of 5-mC for each tissue at each CpG site within the amplicon for Region B. Percentage methylation calculated
from the ratio of mass signals between methylated and non-methylated DNA in each sample. * P≤ 0.05, ** P≤ 0.01, *** P≤ 0.001, **** P≤ 0.0001.
Data are presented as mean %5-mC + SEM
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Aside from one time-point in choriodecidua explants,
TIMP-1 transcription or protein was not changed with
LPS treatment alone. This is in agreement with other
studies which have also reported no change in TIMP-1
levels in the placenta and/or fetal membranes following
LPS stimulation [17, 19, 60]. These studies did however
report an associated increase in MMP-9, thereby altering
the MMP:TIMP ratio and favouring a gelatonlytic state.
Evidence of LPS associated stimulation of MMP-9 is
conflicting; there are a number of reports of increased
MMP-9 mRNA and activity in response to LPS stimula-
tion, [5, 59, 6
1] whilst others report that fetal membranes are
unresponsive to LPS, suggesting upstream me-
diators of MMPs such as prostaglandins and/or
pro-inflammatory cytokines are required [61,
62].
AZA is a demethylating agent that is incorporated into
the DNA as a cytidine analogue, preventing methylation
by irreversibly binding DNMT1 [63]. The resulting loss
of DNMT1 leads to passive hypomethylation of the gen-
ome over successive rounds of cell division, which may
have effects on upstream regulators of TIMP-1. Treat-
ment with AZA has previously been shown to induce
TIMP-1 expression and protein production in cell cul-
ture models [39–43]. Treatment of tissue explants with
AZA alone did not alter TIMP-1 expression or protein
(data not shown). Our tissue culture model utilized tis-
sue explants rather than cell lines, and in light of this,
AZA may not have fully incorporated into the DNA,
Fig. 6 Percentage methylated CpGs in the TIMP-1 promoter in gestational tissues cultured in the presence of lipopolysaccharide (LPS, 5 μg/ml)
with/without prior treatment with 5-aza-deoxycytidine (AZA, 5 μM) (n = 8). a Villous placenta; b Amnion and c Choriodecidua. Tissues from preg-
nancies with male fetuses (n = 5) are shown by white bars and those from pregnancies with female fetuses (n = 3) are shown by cross-hatched
bars. For graphical representation, all CpGs within region A have been combined. Representative epigrams for both male and female tissues are
shown alongside each graph. * P≤ 0.05, ** P≤ 0.01, **** P≤ 0.001. Percentage methylation calculated from the ratio of mass signals between
methylated and non-methylated DNA in each sample. Data are presented as mean %5-mC + SEM
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resulting in reduced action and less pronounced hypo-
methylation [64]. Although we did not measure prolifer-
ation in the tissue explants, glucose uptake by the tissue
explants was measured in culture media and confirmed
that tissues remained viable throughout the culture
period (Table 1). AZA could be directly interacting with
transcription factors [65] or re-organizing chromatin in
such a way that regulatory regions within the promoter
are exposed [66–68], thus facilitating binding of tran-
scription factors which are increased in the presence of
infection. We saw little variation in both TIMP-1
promoter-specific and global methylation (data not
shown) in response to the explant treatments; therefore
the increased TIMP-1 transcription observed in tissues
pre-treated with AZA and subsequently cultured with
LPS indicates that TIMP-1 activation appears to require
an AZA-induced change in chromatin structure, such
that DNA binding sites in the promoter region become
accessible to transcriptional activators. The TIMP-1 pro-
moter contains both ETS and AP-1 binding sites, which,
once bound by effector proteins could potentiate enhanced
TIMP-1 transcription [51]. Work on human hypoxanthine
phosphoribosyltransferase (HPRT) and human-mouse
phosphoglycerate kinase-1 (PK-1) genes suggest that
X-linked genes are unlikely to be primarily silenced
by DNA methylation via direct sequence-specific al-
terations in DNA-protein reactions; rather, methyla-
tion primarily affects chromatin structure [66–68].
TIMP-1 protein was not increased to the same extent
as transcription following culture treatments. Discrepan-
cies between TIMP-1 mRNA and protein have previ-
ously been reported [69]. and the amount of TIMP-1
translation is dependent upon the activation of a number
of signalling pathways [70]. Furthermore, as TIMP-1 is
secreted and has a short half-life, and as such the
amount measured by western blotting in tissue explants
only demonstrate the intracellular contribution of
TIMP-1 production [71, 72].
The placenta itself is inherently variable, and significant
intra-placental variation has been observed due to the vast
range of cell types as well as normal variation in size, shape
and weight [73]. There can also be considerable epigenetic
variation within a placenta, so in addition to the effect of
cell heterogeneity, there could also be random and localized
effects of the uterine environment on the placental epige-
nome [73]. In light of this, every effort was taken to sample
tissue widely across the placenta and fetal membranes.
Conclusions
Intrauterine infection is the leading identifiable cause of
preterm birth, closely followed by PROM, and despite the
implementation of antibiotic treatments to reduce peri-
natal morbidity and mortality, the incidence of preterm
birth is in fact increasing [74, 75]. The use of inhibitors of
metalloproteinases, in particular TIMP-1, provides an at-
tractive option as a potential therapeutic agent. The
marked increase of TIMP-1 that we have seen in gesta-
tional tissues in response to LPS in the context of altered
chromatin structure by AZA therefore suggests that a
pharmacological agent that modifies chromatin structure
could be used as a therapeutic agent in women with intra-
uterine infection and who are at a greater risk of prema-
ture rupture of the fetal membranes.
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